Position in RYTM
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,214,493
+$636,249 QoQ
Shares Held
19,945
+9.9% QoQ
Ownership
0.029%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#128
of 299 holders
Holding Since
Mar 2021
9 quarters on record
Voting authority
Sole 67%
Shared 0%
None 33%
Common Shares in RYTM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPTRUST FINANCIAL ADVISORS holds $167,363,866 across 124 Biotechnology names. RYTM ranks #15 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,464 | $22,736,762 | |
| 2 | RPRX |
Royalty Pharma plc
|
337,298 | $18,912,298 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
35,471 | $17,619,509 | |
| 4 | EXEL |
Exelixis, Inc.
|
303,042 | $16,488,515 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
34,607 | $10,938,926 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
125,946 | $9,857,793 | |
| 7 | CELC |
Celcuity Inc.
|
71,445 | $7,474,575 | |
| 8 | INCY |
Incyte Corp
|
50,301 | $5,702,121 |
All Filings in RYTM
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,214,493 | 19,945 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,578,244 | 18,147 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,961,508 | 18,325 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,843,875 | 18,258 | Shares | Sole | 2025-11-19 | |
| 2025-06-30 | $1,103,992 | 17,471 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $919,400 | 17,357 | Shares | Sole | 2025-05-15 | |
| 2021-09-30 | $248 | 19 | Shares | Sole | 2021-11-16 | |
| 2021-06-30 | $606 | 31 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $659 | 31 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||